Syndax Pharmaceuticals (SNDX) Other financing activities (2015 - 2026)

Syndax Pharmaceuticals' Other financing activities history runs 12 years deep, the most recent figure standing at $7.5 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 1268.81% year-over-year to $7.5 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 333.26% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, down 10.32% from the prior year.
• Other financing activities grew to $7.5 million in Q1 2026 per SNDX's latest filing, from -$5.3 million in the prior quarter.
• Across five years, Other financing activities topped out at $7.5 million in Q1 2026 and bottomed at -$5.3 million in Q4 2025.
• The 5-year median for Other financing activities is $545000.0 (2025), against an average of $1.6 million.
• Across the five-year window, Other financing activities surged 7337.37% in 2022 and sank 934.07% in 2025, its largest moves.
• Year by year, Other financing activities stood at $1.4 million in 2022, then slumped by 92.21% to $112000.0 in 2023, then soared by 466.07% to $634000.0 in 2024, then sank by 934.07% to -$5.3 million in 2025, then jumped by 241.07% to $7.5 million in 2026.
• Per Business Quant, the three latest SNDX Other financing activities figures stand at $7.5 million (Q1 2026), -$5.3 million (Q4 2025), and $6.4 million (Q3 2025).